The molecular pathogenesis of endometrial clear-cell carcinoma: Unclear, uncertain and possibly heterogeneous

Expert Review of Obstetrics and Gynecology

Volumn 7, Issue 2, 2012, Pages 109-112

  Fadare, Oluwole ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

clear cell carcinoma; endometrium; molecular pathogenesis

Indexed keywords

CADHERIN; CD82 ANTIGEN; HEPATOCYTE NUCLEAR FACTOR 1BETA; PROTEIN P53; TRANSCRIPTION FACTOR SOX2;

ARID1A GENE; BAF250A GENE; CLEAR CELL CARCINOMA; CTNNB GENE; DOWN REGULATION; ENDOCYTOSIS; ENDOMETRIUM CARCINOMA; GENE; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE MUTATION; HEMOSTASIS; HETEROZYGOSITY LOSS; HNF1B GENE; HUMAN; KRAS GENE; MICROSATELLITE INSTABILITY; PATHOGENESIS; PHENOTYPE; PTEN GENE; REVIEW; SOX2 GENE; TP53 GENE;

EID: 84857842625     PISSN: 17474108     EISSN: 17474116     Source Type: Journal    
DOI: 10.1586/eog.12.12     Document Type: Review

References (38)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 60, 277-300 (2010
2. Clement PB, Young RH. Non-endometrioid carcinomas of the uterine corpus: A review of their pathology with emphasis on recent advances and problematic aspects. Adv. Anat. Pathol. 11, 117-142 (2004
3. Hecht JL, Mutter GL. Molecular and pathologic aspects of endometrial carcinogenesis. J. Clin. Oncol. 24, 4783-4789 (2006
4. Fadare O, Zheng W. Insights into endometrial serous carcinogenesis and progression. Int. J. Clin. Exp. Pathol. 2, 411-432 (2009
5. Matias-Guiu X, Catasus L, Bussaglia E et al. Molecular pathology of endometrial hyperplasia and carcinoma. Hum. Pathol. 32, 569-577 (2001
6. Zorn KK, Bonome T, Gangi L et al. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin. Cancer Res. 11, 6422-6430 (2005
7. An HJ, Logani S, Isacson C, Ellenson LH. Molecular characterization of uterine clear cell carcinoma. Mod. Pathol. 17, 530-537 (2004
8. DeLair D, Levine D, Bogomolniy F, Wethington S, Han G, Soslow RA. Molecular changes in endometrial clear cell carcinomas and carcinomas with clear cell features. Presented at: 101st Annual Meeting of the United States and Canadian Academy of Pathology. Vancouver, BC, Canada, 17-23 March 2012.
9. Fadare O, Parkash V, Dupont WD et al. The diagnosis of endometrial carcinomas with clear cells by gynecologic pathologists: An interobserver variability study. Presented at: 101st Annual Meeting of the United States and Canadian Academy of Pathology. Vancouver, BC, Canada, 17-23 March 2012.
10. Wong OG, Huo Z, Siu MK et al. Hypermethylation of SOX2 promoter in endometrial carcinogenesis. Obstet. Gynecol. Int. 2010, 682504 (2010
11. Lax SF, Pizer ES, Ronnett BM, Kurman RJ. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression. Hum. Pathol. 29, 551-558 (1998
12. Sun J, Zheng SL, Wiklund F et al. Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12. Nat. Genet. 40, 1153-1155 (2008
13. Tsuchiya A, Sakamoto M, Yasuda J et al. Expression profiling in ovarian clear cell carcinoma: Identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am. J. Pathol. 163, 2503-2512 (2003
14. Fadare O, Liang SX. Diagnostic utility of hepatocyte nuclear factor 1-beta immunoreactivity in endometrial carcinomas: Lack of specificity for endometrial clear cell carcinoma. Appl. Immunohistochem. Mol. Morphol. (2012)(In Press
15. Roberts CW, Orkin SH. The SWI/SNF complex - chromatin and cancer. Nat. Rev. Cancer 4, 133-142 (2004
16. Wilson BG, Roberts CW. SWI/SNF nucleosome remodellers and cancer. Nat. Rev. Cancer 11, 481-492 (2011
17. Jones S, Wang TL, Shih IeM et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 330(6001), 228-231 (2010
18. Wiegand KC, Shah SP, Al-Agha OM et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N. Engl. J. Med. 363, 1532-1543 (2010
19. Wiegand KC, Lee AF, Al-Agha OM et al. Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas. J. Pathol. 224, 328-333 (2011
20. Fadare O, Renshaw IL, Liang SX. Loss of BAF250a expression in endometrial clear cell carcinoma: An assessment of its frequency and clinicopathologic significance. Presented at: 101st Annual Meeting of the United States and Canadian Academy of Pathology. Vancouver, BC, Canada, 17-23 March 2012.
21. Guan B, Mao TL, Panuganti PK et al. Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma. Am. J. Surg. Pathol. 35, 625-632 (2011
22. Kasthuri RS, Taubman MB, Mackman N. Role of tissue factor in cancer. J. Clin. Oncol. 27, 4834-4838 (2009
23. Versteeg HH, Ruf W. Emerging insights in tissue factor-dependent signaling events. Semin. Thromb. Hemost. 32, 24-32 (2006
24. Fadare O, Renshaw IL, Liang SX. Expression of tissue factor and heparanase in endometrial clear cell carcinoma: Possible role for tissue factor in thromboembolic events. Int. J. Gynecol. Pathol. 30, 252-261 (2011
25. Lee L, Garrett L, Lee H, Oliva E, Horowitz N, Duska LR. Association of clear cell carcinoma of the endometrium with a high rate of venous thromboembolism. J. Reprod. Med. 54, 133-138 (2009
26. Zheng W, Yi X, Fadare O et al. The oncofetal protein IMP3: A novel biomarker for endometrial serous carcinoma. Am. J. Surg. Pathol. 32(2), 304-315 (2008
27. Jeanes A, Gottardi CJ, Yap AS. Cadherins and cancer: How does cadherin dysfunction promote tumor progression? Oncogene 27, 6920-6929 (2008
28. Hirohashi S. Inactivation of the E-cadherin-mediated cell adhesion system in human cancers. Am. J. Pathol. 153, 333-339 (1998
29. Holcomb K, Delatorre R, Pedemonte B, McLeod C, Anderson L, Chambers J. E-cadherin expression in endometrioid, papillary serous, and clear cell carcinoma of the endometrium. Obstet. Gynecol. 100(6), 1290-1295 (2002
30. Arai T, Watanabe J, Kawaguchi M et al. Clear cell adenocarcinoma of the endometrium is a biologically distinct entity from endometrioid adenocarcinoma. Int. J. Gynecol. Cancer 16(1), 391-395 (2006
31. Singh M, Spoelstra NS, Jean A et al. ZEB1 expression in type I vs type II endometrial cancers: A marker of aggressive disease. Mod. Pathol. 21, 912-923 (2008
32. Arpin M, Chirivino D, Naba A, Zwaenepoel I. Emerging role of ERM proteins in cell adhesion and migration. Cell Adh. Migr. 1(5), 199-206 (2011
33. Louvet-Vallee S. ERM proteins: From cellular architecture to cell signaling. Biol. Cell 92, 305-316 (2000
34. Mhawech-Fauceglia P, Wang D, Lele S, Frederick PJ, Pejovic T, Liu S. Claudin7 and moesin in endometrial adenocarcinoma; a retrospective study of 265 patients. BMC Res. Notes 5(1), 65 (2012
35. Mhawech-Fauceglia P, Wang D, Syriac S et al. Synuclein-g (SNCG) protein expression is associated with poor outcome in endometrial adenocarcinoma. Gynecol. Oncol. 124, 148-152 (2012
36. Briese J, Schulte HM, Sajin M et al. Correlations between reduced expression of the metastasis suppressor gene KAI-1 and accumulation of p53 in uterine carcinomas and sarcomas. Virchows Arch. 453(1), 89-96 (2008
37. Miranti CK. Controlling cell surface dynamics and signaling: How CD82/KAI1 suppresses metastasis. Cell Signal. 21, 196-211 (2009
38. Guan B, Wang TL, Shih IeM. ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. Cancer Res. 71, 6718-6727 (2011